In a phase I/II trial, 11 patients with relapsed/refractory CD19-positive cancers were given escalating doses of these CD19 CAR NK cells after lymphodepleting chemotherapy with fludarabine and cyclophosphamide [13••]. The gene discussed is CD19; the disease is cancer.